NEW YORK – Applied Spectral Imaging (ASI) and Kromatid said on Tuesday they have entered into a strategic partnership.
Under the terms of the agreement, ASI obtained worldwide rights to market Kromatid's Pinpoint fluorescence in situ hybridization (PPF) probes and assay services, used to study genomic structural variants, alongside its Genasis imaging platform.